251 results on '"Colombel, J"'
Search Results
2. Adalimumab for the treatment of fistulas in patients with Crohn's disease
3. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis
4. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine
5. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon (gamma) antibody, in patients with moderate to severe Crohn's disease
6. Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation
7. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
8. European evidence based consensus on the diagnosis and management of Crohn's disease: current management
9. Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999)
10. A randomised placebo controlled trial of pegylated interferon α in active ulcerative colitis
11. CARD4/NOD1 is not involved in inflammatory bowel disease. (Inflammatory Bowel Disease)
12. Local appendiceal dysbiosis: the missing link between the appendix and ulcerative colitis?
13. Is detection of JC virus DNA in blood a valuable screening test for progressive multifocal leukoencephalopathy in Crohn’s disease patients eligible for anti-α4 integrin therapy?
14. Small-bowel ulcerations at wireless capsule endoscopy: go the whole way
15. Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis
16. Quantitative measurement and visual assessment of ileal Crohn’s disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein
17. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn’s disease
18. Wireless capsule endoscopy versus ileocolonoscopy for the diagnosis of postoperative recurrence of Crohn’s disease: a prospective study
19. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial
20. Perinatal passive smoke exposure may be more important than childhood exposure in the risk of developing childhood IBD: Author’s reply
21. Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease
22. ITPA genotyping test does not improve detection of Crohn’s disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression
23. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study
24. Infliximab failure in cap polyposis
25. Dysbiosis as a prerequisite for IBD
26. Dysbiosis in inflammatory bowel disease
27. Early development of stricturing or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype
28. Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohnʼs disease
29. Mucin gene expression in intestinal epithelial cells in Crohnʼs disease
30. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohnʼs disease
31. Antibiotics in Crohnʼs disease
32. Genetically related Escherichia coli strains associated with Crohnʼs disease
33. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohnʼs disease
34. Genetic analyses of chromosome 12 loci in Crohnʼs disease
35. Anticipating the onset of inflammatory bowel disease
36. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role
37. Anticipation in familial Crohn's disease
38. Abnormal mucus in cap polyposis
39. The inflammatory bowel disease (IBD1) locus on chromosome 16: Suggestive evidence of linkage to ulcerative colitis 22.04
40. Safety, tolerance and activity of multiple doses of subcutaneous recombinant human interleukin-10 (rHuIL-10) in patients with mild to moderate active Crohn's disease 11.02
41. Association of HLA class II genes with susceptibility to Crohn's disease
42. OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn’s Disease (CD) Refractory to anti-TNFΑ: UNITI-1
43. OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), AHuman MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn’s Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2: Abstract OC-007 Table 1
44. Is detection of JC virus DNA in blood a valuable screening test for progressive multifocal leukoencephalopathy in Crohn's disease patients eligible for anti-[alpha]4 integrin therapy?
45. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis
46. PTU-055 Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis
47. PTU-111 Baseline C reactive protein is associated with disease progression in patients with Crohn's disease: Abstract PTU-111 Table 1
48. PWE-254 Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease
49. PWE-260 Optimal C reactive protein cut-off point for predicting hospitalisation in patients with moderately active Crohn's disease
50. PTU-108 Induction of remission with adalimumab in patients with moderate Crohn's disease: subanalysis of CLASSIC I: Abstract PTU-108 Table 1
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.